182 related articles for article (PubMed ID: 17520175)
1. Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.
Horváth V; Soucek K; Svihálková-Sindlerová L; Vondrácek J; Blanárová O; Hofmanová J; Sova P; Kozubík A
Invest New Drugs; 2007 Oct; 25(5):435-43. PubMed ID: 17520175
[TBL] [Abstract][Full Text] [Related]
2. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
3. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
[TBL] [Abstract][Full Text] [Related]
4. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
[TBL] [Abstract][Full Text] [Related]
5. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
6. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
Turánek J; Kasná A; Záluská D; Neca J; Kvardová V; Knötigová P; Horváth V; SIndlerová L; Kozubík A; Sova P; Kroutil A; Zák F; Mistr A
Anticancer Drugs; 2004 Jun; 15(5):537-43. PubMed ID: 15166629
[TBL] [Abstract][Full Text] [Related]
7. The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.
Roubalová E; Kvardová V; Hrstka R; Borilová S; Michalová E; Dubská L; Müller P; Sova P; Vojtesek B
Invest New Drugs; 2010 Aug; 28(4):445-53. PubMed ID: 19499188
[TBL] [Abstract][Full Text] [Related]
8. Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
Tu Y; Kim E; Gao Y; Rankin GO; Li B; Chen YC
Int J Oncol; 2016 Jun; 48(6):2657-65. PubMed ID: 27082635
[TBL] [Abstract][Full Text] [Related]
9. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
10. Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway.
Jelínková I; Šafaříková B; Vondálová Blanářová O; Skender B; Hofmanová J; Sova P; Moyer MP; Kozubík A; Kolář Z; Ehrmann J; Hyršlová Vaculová A
Biochem Pharmacol; 2014 Dec; 92(3):415-24. PubMed ID: 25285768
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines.
Pestell KE; Medlow CJ; Titley JC; Kelland LR; Walton MI
Int J Cancer; 1998 Sep; 77(6):913-8. PubMed ID: 9714063
[TBL] [Abstract][Full Text] [Related]
13. The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.
Kvardova V; Hrstka R; Walerych D; Muller P; Matoulkova E; Hruskova V; Stelclova D; Sova P; Vojtesek B
Mol Cancer; 2010 Jun; 9():147. PubMed ID: 20550649
[TBL] [Abstract][Full Text] [Related]
14. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI
Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
[TBL] [Abstract][Full Text] [Related]
16. Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line.
Lee BJ; Chon KM; Kim YS; An WG; Roh HJ; Goh EK; Wang SG
Chemotherapy; 2005 May; 51(2-3):103-10. PubMed ID: 15886465
[TBL] [Abstract][Full Text] [Related]
17. Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells.
Vondálová Blanářová O; Jelínková I; Hyršlová Vaculová A; Sova P; Hofmanová J; Kozubík A
Cell Prolif; 2013 Dec; 46(6):665-76. PubMed ID: 24118195
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase.
Li X; Wang G; Zhao J; Ding H; Cunningham C; Chen F; Flynn DC; Reed E; Li QQ
Cell Mol Life Sci; 2005 Apr; 62(7-8):894-904. PubMed ID: 15868412
[TBL] [Abstract][Full Text] [Related]
19. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
20. Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells.
Kalimutho M; Minutolo A; Grelli S; Federici G; Bernardini S
Acta Pharmacol Sin; 2011 Nov; 32(11):1387-96. PubMed ID: 21927014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
